BioMinhai's Live Attenuated Varicella Vaccine Receives DRAP Approval for Launch in Pakistan

BioMinhai announced that its live attenuated varicella vaccine has been granted marketing authorization by Pakistan’s Drug Regulatory Authority (DRAP).

The approval clears the varicella vaccine for commercial launch in a country of 250 million inhabitants—now adding 6.9 million births annually—and aligns with Pakistan’s Expanded Programme on Immunization, whose procurement budget is scheduled to reach approximately US $80 million by 2029.

With varicella causing an estimated 140 million cases worldwide each year and no curative therapy available, the registration delivers a new, prevention option to Pakistani health-care providers and supports national efforts to reduce varicella-related morbidity and mortality.

The milestone is another step toward BioKangtai’s mission to equalize access to high-quality vaccines across diverse populations and to advance the global goal of eliminating vaccine-preventable diseases.